http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103961684-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 |
| filingDate | 2014-05-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103961684-B |
| titleOfInvention | The application of Sha Kuilawei in the medicine of preparation prevention or treatment pulmonary fibrosis |
| abstract | The invention provides the new medicine use of Sha Kuilawei, be specifically related to Sha Kuilawei by suppressing I type alveolar epithelial cells apoptosis, do you promote the glycosylated end-product receptor (receptor of I type alveolar epithelial cells? for? advanced? glycation? endproducts, RAGE) thus expression suppress acute lung injury/acute respiratory distress syndrome (ALI/ARDS) and the developing of pulmonary fibrosis so that prevention or treat ALI/ARDS and pulmonary fibrosis. In above-mentioned application, its injection using dosage scope is 50mg～2000mg; Preferably 50～1000mg. It orally uses dosage range is 200mg～6000mg; Preferably 400～6000mg. |
| priorityDate | 2014-05-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 56.